Cervical dystonia: an update on therapeutics

References

• Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol. 1998;78:1–10.
   PubMedGoogle Scholar
• Balint B, Mencacci NE, Valente EM, et al. Dystonia. Nat Rev Dis Prim. 2018;4:25.
   PubMed Web of Science ®Google Scholar
• Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–873.
   PubMed Web of Science ®Google Scholar
• Smit M, Kamphuis ASJ, Bartels AL, et al. Fatigue, sleep disturbances, and their influence on quality of life in cervical dystonia patients. Mov Disord Clin Pract. 2017;4:517–523.
   PubMed Web of Science ®Google Scholar
• Molho ES, Stacy M, Gillard P, et al. Impact of Cervical Dystonia on work productivity: an analysis from a patient registry. Mov Disord Clin Pract. 2016;3:130–138.
   PubMed Web of Science ®Google Scholar
• Charles PD, Adler CH, Stacy M, et al. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014;261:1309–1319.
   PubMed Web of Science ®Google Scholar
• Merola A, Dwivedi A, Shaikh A, et al. Head tremor at disease onset: an ataxic phenotype of cervical dystonia. J Neurol. Forthcoming 2019 .
   Google Scholar
• Andrews C, Aviles-Olmos I, Hariz M, et al. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry. 2010;81:1383–1389.
   PubMed Web of Science ®Google Scholar
• Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11:139–152.
   PubMed Web of Science ®Google Scholar
• Pirio Richardson S, Wegele AR, Skipper B, et al. Dystonia treatment: patterns of medication use in an international cohort. Neurology. 2017;88:543–550.
   PubMed Web of Science ®Google Scholar
• Wijemanne S, Jankovic J. Dopa-responsive dystonia—clinical and genetic heterogeneity. Nat Rev Neurol. 2015;11:414.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86:1818–1826.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32:1131–1138.
   PubMed Web of Science ®Google Scholar
• Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018;147:84–88.
   PubMed Web of Science ®Google Scholar
• Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40:1213–1218.
   PubMed Web of Science ®Google Scholar
• Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35:208–214.
   PubMed Web of Science ®Google Scholar
• Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry. 1998;64:13–17.
   PubMed Web of Science ®Google Scholar
• Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439–1446.
   PubMed Web of Science ®Google Scholar
• Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431–1438.
   PubMed Web of Science ®Google Scholar
• Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308:103–109.
   PubMed Web of Science ®Google Scholar
• Evidente VGH, Fernandez HH, LeDoux MS, et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin((R))) in cervical dystonia. J Neural Transm. 2013;120:1699–1707.
   PubMed Web of Science ®Google Scholar
• Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16:316–323.
   PubMed Web of Science ®Google Scholar
• Kaji R, Shimizu H, Takase T, et al. A double-blind comparative study to evaluate the efficacy and safety of NerBloc(R) (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia. Brain Nerve. 2013;65:203–211.
   PubMedGoogle Scholar
• Poewe W, Burbaud P, Castelnovo G, et al. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial. Mov Disord. 2016;31:1649–1657.
   PubMed Web of Science ®Google Scholar
• Lew MF, Brashear A, Dashtipour K, et al. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci. 2018;128:619–626.
   PubMed Web of Science ®Google Scholar
• Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46:1066–1072.
   PubMed Web of Science ®Google Scholar
• Misra VP, Colosimo C, Charles D, et al. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. J Neurol. 2018;265:402–409.
   PubMed Web of Science ®Google Scholar
• Schramm A, Huber D, Mobius C, et al. Involvement of obliquus capitis inferior muscle in dystonic head tremor. Parkinsonism Relat Disord. 2017;44:119–123.
   PubMed Web of Science ®Google Scholar
• Van Gerpen JA, Matsumoto JY, Ahlskog JE, et al. Utility of an EMG mapping study in treating cervical dystonia. Muscle Nerve. 2000;23:1752–1756.
   PubMed Web of Science ®Google Scholar
• Erro R, Bhatia KP, Esposito M, et al. The role of polymyography in the treatment of cervical dystonia. J Neurol Germany. 2016;263:1663–1664.
   PubMedGoogle Scholar
• Kilbane C, Ostrem J, Galifianakis N, et al. Multichannel electromyographic mapping to optimize onabotulinumtoxinA efficacy in cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2012;2.
   PubMedGoogle Scholar
• Nijmeijer SWR, Koelman JHTM, Standaar TSM, et al. Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord. 2013;19:533–538.
   PubMed Web of Science ®Google Scholar
• Hong JS, Sathe GG, Niyonkuru C, et al. Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia. Muscle Nerve. 2012;46:535–539.
   PubMed Web of Science ®Google Scholar
• Ramirez-Castaneda J, Jankovic J, Comella C, et al. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28:1775–1783.
   PubMed Web of Science ®Google Scholar
• Samotus O, Lee J, Jog M. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance. J Neurol. 2018;265:1269–1278.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Adler CH, Charles D, et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015;349:84–93.
   PubMed Web of Science ®Google Scholar
• Wissel J, Kanovsky P, Ruzicka E, et al. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled. J Neurol. 2001;248:1073–1078.
   PubMed Web of Science ®Google Scholar
• Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783–791.
   PubMed Web of Science ®Google Scholar
• Trosch RM, Espay AJ, Truong D, et al. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: the ANCHOR-CD registry. J Neurol Sci. 2017;376:84–90.
   PubMed Web of Science ®Google Scholar
• Quagliato EMAB, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2010;33:22–26.
   PubMed Web of Science ®Google Scholar
• Barbosa PM, Rodrigues GR, de Oliveira DS, et al. Comparison between dysport and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2015;38:221–226.
   PubMed Web of Science ®Google Scholar
• Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23:510–517.
   PubMed Web of Science ®Google Scholar
• Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701–707.
   PubMed Web of Science ®Google Scholar
• Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423–1429.
   PubMed Web of Science ®Google Scholar
• Berman B, Seeberger L, Kumar R. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord. 2005;20:233–237.
   PubMed Web of Science ®Google Scholar
• Duarte GS, Castelao M, Rodrigues FB, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016;10:CD004314.
   PubMedGoogle Scholar
• Han Y, Stevens AL, Dashtipour K, et al. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol. 2016;263:772–780.
   PubMed Web of Science ®Google Scholar
• Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016;13:CD004315.
   Google Scholar
• Fernandez HH, Pappert EJ, Comella CL, et al. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naive subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;2: pii:tre-03-140-2921-1.
   Google Scholar
• Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6–12.
   PubMed Web of Science ®Google Scholar
• Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72:459–462.
   PubMed Web of Science ®Google Scholar
• Yun JY, Kim JW, Kim H-T, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord. 2015;30:206–213.
   PubMed Web of Science ®Google Scholar
• Dressler D, Tacik P, Adib Saberi F. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox((R))) and incobotulinumtoxinA (Xeomin ((R))). J Neural Transm. 2014;121:29–31.
   PubMed Web of Science ®Google Scholar
• Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014;90:344–348.
   PubMed Web of Science ®Google Scholar
• Dressler D, Paus S, Seitzinger A, et al. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry. 2013;84:1014–1019.
   PubMed Web of Science ®Google Scholar
• Kessler KR, Skutta M, Benecke R, et al. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol. 1999;246:265–274.
   PubMed Web of Science ®Google Scholar
• Smit M, Kuiper A, Han V, et al. Psychiatric co-morbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: results of a controlled study. Parkinsonism Relat Disord. 2016;30:7–12.
   PubMed Web of Science ®Google Scholar
• Camargo CHF, Cattai L, Teive HAG. Pain relief in cervical dystonia with botulinum toxin treatment. Toxins (Basel). 2015;7:2321–2335.
   PubMed Web of Science ®Google Scholar
• Moll M, Rosenthal D, Hefter H. Quality of life in long-term botulinum toxin treatment of cervical dystonia: results of a cross sectional study. Parkinsonism Relat Disord. 2018;57:63–67.
   PubMed Web of Science ®Google Scholar
• Mordin M, Masaquel C, Abbott C, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open. 2014;4:e005150.
   PubMed Web of Science ®Google Scholar
• Kongsaengdao S, Maneeton N, Maneeton B. Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study. Neuropsychiatr Dis Treat. 2018;14:1119–1124.
   PubMed Web of Science ®Google Scholar
• Bentivoglio AR, Di Stasio E, Mulas D, et al. Long-term abobotulinumtoxin A treatment of cervical dystonia. Neurotox Res. 2017;32:291–300.
   PubMed Web of Science ®Google Scholar
• Duarte GS, Rodrigues FB, Ferreira JJ, et al. Adverse events with botulinum toxin treatment in cervical dystonia: how much should we blame placebo? Parkinsonism Relat. Disord. 2018;56:16–19.
   Google Scholar
• Jinnah HA, Comella CL, Perlmutter J, et al. Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy? Toxicon. 2018;147:89–95.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991;48:1253–1256.
   PubMedGoogle Scholar
• Jinnah HA, Goodmann E, Rosen AR, et al. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol. 2016;263:1188–1194.
   PubMed Web of Science ®Google Scholar
• Kanovsky P, Dufek J, Halackova H, et al. Change in the pattern of cervical dystonia might be the cause of benefit loss during botulinum toxin treatment. Eur J Neurol. 1997;4:79–84.
   PubMed Web of Science ®Google Scholar
• Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998;50:1624–1629.
   PubMed Web of Science ®Google Scholar
• Kessler KR, Benecke R. The EBD test–a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord. 1997;12:95–99.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Gooch CL, Greene PE. Extensor digitorum brevis test and resistance to botulinum toxin type A. Muscle Nerve. 2002;26:828–831.
   PubMed Web of Science ®Google Scholar
• Brin MF, Comella CL, Jankovic J, et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353–1360.
   PubMed Web of Science ®Google Scholar
• Albrecht P, Jansen A, Lee J-I, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92:e48–e54.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006;9:145–148.
   PubMed Web of Science ®Google Scholar
• Oshima M, Deitiker P, Jankovic J, et al. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016;300:36–46.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Immunoresistance to Botulinum Toxins. Neurology. Forthcoming 2019.
   Google Scholar
• Jagota P, Kaewwilai L, Boonrod N, et al. Impact of neu-botulinumtoxinA on the severity and quality of life of cervical dystonia patients. Tremor Other Hyperkinet Mov (N Y). 2016;6:407.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Truong D, Patel AT, et al. Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract. 2018;5:273–282.
   PubMed Web of Science ®Google Scholar
• Naumann M, Boo LM, Ackerman AH, et al. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120:275–290.
   PubMed Web of Science ®Google Scholar
• Krauss JK, Pohle T, Weber S, et al. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet. 1999;354:837–838.
   PubMed Web of Science ®Google Scholar
• Kiss ZHT, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain. 2007;130:2879–2886.
   PubMed Web of Science ®Google Scholar
• Pretto TE, Dalvi A, Kang UJ, et al. A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg. 2008;109:405–409.
   PubMed Web of Science ®Google Scholar
• Cacciola F, Farah JO, Eldridge PR, et al. Bilateral deep brain stimulation for cervical dystonia: long-term outcome in a series of 10 patients. Neurosurgery. 2010;67:957–963.
   PubMed Web of Science ®Google Scholar
• Skogseid IM, Ramm-Pettersen J, Volkmann J, et al. Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol. 2012;19:610–615.
   PubMed Web of Science ®Google Scholar
• Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol. 2014;13:875–884.
   PubMed Web of Science ®Google Scholar
• Chung M, Huh R. Different clinical course of pallidal deep brain stimulation for phasic- and tonic-type cervical dystonia. Acta Neurochir (Wien). 2016;58:171–180.
   Google Scholar
• Kleiner-Fisman G, Lin Liang GS, Moberg PJ, et al. Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life. J Neurosurg. 2007;107:29–36.
   PubMed Web of Science ®Google Scholar
• Ostrem JL, Racine CA, Glass GA, et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology. 2011;76:870–878.
   PubMed Web of Science ®Google Scholar
• Ostrem JL, San Luciano M, Dodenhoff KA, et al. Subthalamic nucleus deep brain stimulation in isolated dystonia: a 3-year follow-up study. Neurology. 2017;88:25–35.
   PubMed Web of Science ®Google Scholar
• Bertrand CM. Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg Neurol. 1993;40:96–103.
   PubMed Web of Science ®Google Scholar
• Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, et al. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg. 2003;98:1247–1254.
   PubMed Web of Science ®Google Scholar
• Bergenheim AT, Nordh E, Larsson E, et al. Selective peripheral denervation for cervical dystonia: long-term follow-up. J Neurol Neurosurg Psychiatry. 2015;86:1307–1313.
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Mancini F, Balloni L, et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord. 2006;21:2240–2243.
   PubMed Web of Science ®Google Scholar
• van den Dool J, Visser B, Koelman JHTM, et al. Long-term specialized physical therapy in cervical dystonia: outcomes of a randomized controlled trial. Arch Phys Med Rehabil. 2019. pii:S0003:30091-30097.[Epub ahead of print]
   PubMedGoogle Scholar
• Bleton J-P. Physiotherapy of focal dystonia: a physiotherapist’s personal experience. Eur J Neurol. 2010;17(Suppl1):107–112.
   PubMedGoogle Scholar
• De Pauw J, Van der Velden K, Meirte J, et al. The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol. 2014;261:1857–1865.
   PubMed Web of Science ®Google Scholar
• Bega D, Park K, Grimone A, et al. Acupuncture as adjuvant therapy for the management of cervical dystonia. Med Acupunct. 2018;30:198–203.
   PubMed Web of Science ®Google Scholar
• Patel N, Hanfelt J, Marsh L, et al. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014;85:882–884.
   PubMed Web of Science ®Google Scholar